Evaluation of the efficacy and safety of Adalimumab and methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome
Phase 3
Recruiting
- Conditions
- COVID-19 Disease.COVID-19U07.2,
- Registration Number
- IRCT20200406046963N2
- Lead Sponsor
- Artesh University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patient with moderate to severe Covid-19 admitted to ICU
PaO2/FiO2 Less than 300
LDH more than 450
Progression of disease severity and not responding to standard treatment
prediction of intubation for next 24 hours
Exclusion Criteria
Uncontrolled diabetes mellitus
Active GI bleeding
history of corticosteroid hypersensitivity
sever electrolyte imbalances
Procalcitonin more than 0.5
active bacterial, viral ( HIV, Hepatitis) and fungal infection
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality rate. Timepoint: from including to study to 60 days. Method of measurement: observation.
- Secondary Outcome Measures
Name Time Method